Increased sphingosine 1-phosphate mediates inflammation and fibrosis in tubular injury in diabetic nephropathy

Clinical and Experimental Pharmacology and Physiology

Volumn 43, Issue 1, 2016, Pages 56-66

  Yaghobian, Dania ^a   Don, Anthony S ^b   Yaghobian, Sarina ^a   Chen, Xinming ^a   Pollock, Carol A ^a   Saad, Sonia ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Diabetes; Fibrosis; Nephropathy; Sphingosine kinase

Indexed keywords

COLLAGEN TYPE 4; FIBRONECTIN; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN P42; PROTEIN P44; SKI II; SMALL INTERFERING RNA; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; ENZYME INHIBITOR; LYSOPHOSPHOLIPID; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOPROTEIN; PHOSPHOTRANSFERASE; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE; SPHINGOSINE KINASE; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; EXTRACELLULAR MATRIX; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INTERSTITIAL NEPHRITIS; KIDNEY CORTEX; KIDNEY FIBROSIS; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE DAMAGE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; WILD TYPE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; DEFICIENCY; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; INJURIES; KIDNEY TUBULE; MALE; METABOLISM; PATHOLOGY;

ANIMALS; BIOMARKERS; CELL LINE; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EXTRACELLULAR MATRIX; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROSIS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE SILENCING; GLUCOSE; HUMANS; INFLAMMATION; KIDNEY CORTEX; KIDNEY TUBULES; LYSOPHOSPHOLIPIDS; MALE; MICE; NF-KAPPA B; PHOSPHOPROTEINS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); SPHINGOSINE; TRANSCRIPTION FACTOR AP-1; TRANSFORMING GROWTH FACTOR BETA;

EID: 84954408916     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12494     Document Type: Article

References (36)

1. Schena FP, Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy. J. Am. Soc. Nephrol. 2005; 16(Suppl. 1): S30-3.
2. Brosius III FC. New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev. Endocr. Metab. Disord. 2008; 9: 245-54.
3. Fioretto P, Mauer M. Histopathology of diabetic nephropathy. Semin. Nephrol. 2007; 27: 195-207.
4. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury? Kidney Int. 1999; 56: 1627-37.
5. Wu CC, Sytwu HK, Lin YF. Cytokines in diabetic nephropathy. Adv. Clin. Chem. 2012; 56: 55-74.
6. Hills CE, Squires PE. The role of TGF-beta and epithelial-to mesenchymal transition in diabetic nephropathy. Cytokine Growth Factor Rev. 2011; 22: 131-9.
7. Lehmann R, Schleicher ED. Molecular mechanism of diabetic nephropathy. Clin. Chim. Acta. 2000; 297: 135-44.
8. Chiarelli F, Gaspari S, Marcovecchio ML. Role of growth factors in diabetic kidney disease. Horm. Metab. Res. 2009; 41: 585-93.
9. Hait NC, Oskeritzian CA, Paugh SW, Milstien S, Spiegel S. Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim. Biophys. Acta 2006; 1758: 2016-26.
10. Jo SK, Bajwa A, Awad AS, Lynch KR, Okusa MD. Sphingosine-1-phosphate receptors: Biology and therapeutic potential in kidney disease. Kidney Int. 2008; 73: 1220-30.
11. Wang L, Xing XP, Holmes A et al. Activation of the sphingosine kinase-signaling pathway by high glucose mediates the proinflammatory phenotype of endothelial cells. Circ. Res. 2005; 97: 891-9.
12. You B, Ren A, Yan G, Sun J. Activation of sphingosine kinase-1 mediates inhibition of vascular smooth muscle cell apoptosis by hyperglycemia. Diabetes 2007; 56: 1445-53.
13. Geoffroy K, Wiernsperger N, Lagarde M, El Bawab S. Bimodal effect of advanced glycation end products on mesangial cell proliferation is mediated by neutral ceramidase regulation and endogenous sphingolipids. J. Biol. Chem. 2004; 279: 34343-52.
14. Geoffroy K, Troncy L, Wiernsperger N, Lagarde M, El Bawab S. Glomerular proliferation during early stages of diabetic nephropathy is associated with local increase of sphingosine-1-phosphate levels. FEBS Lett. 2005; 579: 1249-54.
15. French KJ, Upson JJ, Keller SN, Zhuang Y, Yun JK, Smith CD. Antitumor activity of sphingosine kinase inhibitors. J. Pharmacol. Exp. Ther. 2006; 318: 596-603.
16. Vallon V, Thomson SC. Renal function in diabetic disease models: The tubular system in the pathophysiology of the diabetic kidney. Annu. Rev. Physiol. 2012; 74: 351-75.
17. Kono Y, Nishiuma T, Nishimura Y et al. Sphingosine kinase 1 regulates differentiation of human and mouse lung fibroblasts mediated by TGF-beta1. Am. J. Respir. Cell Mol. Biol. 2007; 37: 395-404.
18. Milara J, Navarro R, Juan G et al. Sphingosine-1-phosphate is increased in patients with idiopathic pulmonary fibrosis and mediates epithelial to mesenchymal transition. Thorax 2012; 67: 147-56.
19. Yin Z, Fan L, Jia H, Li C, Zhang R, Wang H. S1P1 and S1P3 are potential markers of cardiac microangiopathy in diabetes. Med. Hypotheses 2012; 79: 168-70.
20. Boslem E, Meikle PJ, Biden TJ. Roles of ceramide and sphingolipids in pancreatic beta-cell function and dysfunction. Islets 2012; 4: 177-87.
21. Cantrell Stanford J, Morris AJ, Sunkara M, Popa GJ, Larson KL, Ozcan S. Sphingosine 1-phosphate (S1P) regulates glucose-stimulated insulin secretion in pancreatic beta cells. J. Biol. Chem. 2012; 287: 13457-64.
22. Schmitz-Peiffer C. Targeting ceramide synthesis to reverse insulin resistance. Diabetes 2010; 59: 2351-3.
23. Lan T, Liu W, Xie X et al. Sphingosine kinase-1 pathway mediates high glucose-induced fibronectin expression in glomerular mesangial cells. Mol. Endocrinol. 2011; 25: 2094-105.
24. Xin C, Ren S, Eberhardt W, Pfeilschifter J, Huwiler A. The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells. Br. J. Pharmacol. 2006; 147: 164-74.
25. Lan T, Shen X, Liu P et al. Berberine ameliorates renal injury in diabetic C57BL/6 mice: Involvement of suppression of SphK-S1P signaling pathway. Arch. Biochem. Biophys. 2010; 502: 112-20.
26. Katsuma S, Hada Y, Ueda T et al. Signalling mechanisms in sphingosine 1-phosphate-promoted mesangial cell proliferation. Genes Cells 2002; 7: 1217-30.
27. Bajwa A, Jo SK, Ye H et al. Activation of sphingosine-1-phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury. J. Am. Soc. Nephrol. 2010; 21: 955-65.
28. Awad AS, Rouse MD, Khutsishvili K et al. Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes. Kidney Int. 2011; 79: 1090-8.
29. Brinkmann V, Billich A, Baumruker T et al. Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug. Discov. 2010; 9: 883-97.
30. Huwiler A, Pfeilschifter J. New players on the center stage: Sphingosine 1-phosphate and its receptors as drug targets. Biochem. Pharmacol. 2008; 75: 1893-900.
31. Ren S, Babelova A, Moreth K et al. Transforming growth factor-beta2 upregulates sphingosine kinase-1 activity, which in turn attenuates the fibrotic response to TGF-beta2 by impeding CTGF expression. Kidney Int. 2009; 76: 857-67.
32. Sanchez AP, Sharma K. Transcription factors in the pathogenesis of diabetic nephropathy. Expert Rev. Mol. Med. 2009; 11: e13.
33. Hill C, Flyvbjerg A, Gronbaek H et al. The renal expression of transforming growth factor-beta isoforms and their receptors in acute and chronic experimental diabetes in rats. Endocrinology 2000; 141: 1196-208.
34. Allende ML, Sasaki T, Kawai H et al. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J. Biol. Chem. 2004; 279: 52487-92.
35. Bielawski J, Szulc ZM, Hannun YA, Bielawska A. Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods 2006; 39: 82-91.
36. Wong JW, Abuhusain HJ, McDonald KL, Don AS. MMSAT: Automated quantification of metabolites in selected reaction monitoring experiments. Anal. Chem. 2012; 84: 470-4.